133 related articles for article (PubMed ID: 23959956)
1. Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2.
Biernacka KM; Uzoh CC; Zeng L; Persad RA; Bahl A; Gillatt D; Perks CM; Holly JM
Endocr Relat Cancer; 2013 Oct; 20(5):741-51. PubMed ID: 23959956
[TBL] [Abstract][Full Text] [Related]
2. Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.
Biernacka KM; Persad RA; Bahl A; Gillatt D; Holly JM; Perks CM
Endocr Relat Cancer; 2017 Jan; 24(1):17-30. PubMed ID: 27754854
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel.
Uzoh CC; Holly JM; Biernacka KM; Persad RA; Bahl A; Gillatt D; Perks CM
Br J Cancer; 2011 May; 104(10):1587-93. PubMed ID: 21487405
[TBL] [Abstract][Full Text] [Related]
4. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
[TBL] [Abstract][Full Text] [Related]
5. Trichostatin A reverses the chemoresistance of lung cancer with high IGFBP2 expression through enhancing autophagy.
Tang D; Yao R; Zhao D; Zhou L; Wu Y; Yang Y; Sun Y; Lu L; Gao W
Sci Rep; 2018 Mar; 8(1):3917. PubMed ID: 29500455
[TBL] [Abstract][Full Text] [Related]
6. Hyper-acetylation contributes to the sensitivity of chemo-resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A.
Xu Q; Liu X; Zhu S; Hu X; Niu H; Zhang X; Zhu D; Nesa EU; Tian K; Yuan H
J Cell Mol Med; 2018 Mar; 22(3):1909-1922. PubMed ID: 29327812
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
Hwang JJ; Kim YS; Kim MJ; Kim DE; Jeong IG; Kim CS
J Urol; 2010 Dec; 184(6):2557-64. PubMed ID: 21030039
[TBL] [Abstract][Full Text] [Related]
8. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells.
Kojima K; Ohhashi R; Fujita Y; Hamada N; Akao Y; Nozawa Y; Deguchi T; Ito M
Biochem Biophys Res Commun; 2008 Aug; 373(3):423-8. PubMed ID: 18573234
[TBL] [Abstract][Full Text] [Related]
9. IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.
Myers AL; Lin L; Nancarrow DJ; Wang Z; Ferrer-Torres D; Thomas DG; Orringer MB; Lin J; Reddy RM; Beer DG; Chang AC
Oncotarget; 2015 Sep; 6(28):25897-916. PubMed ID: 26317790
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells.
Forde JC; Perry AS; Brennan K; Martin LM; Lawler MP; Lynch TH; Hollywood D; Marignol L
Urol Oncol; 2012; 30(6):912-9. PubMed ID: 21176881
[TBL] [Abstract][Full Text] [Related]
11. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
Zeng J; Liu W; Fan YZ; He DL; Li L
Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
[No Abstract] [Full Text] [Related]
12. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
[TBL] [Abstract][Full Text] [Related]
13. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells.
Kikuno N; Shiina H; Urakami S; Kawamoto K; Hirata H; Tanaka Y; Majid S; Igawa M; Dahiya R
Int J Cancer; 2008 Aug; 123(3):552-60. PubMed ID: 18431742
[TBL] [Abstract][Full Text] [Related]
14. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells.
Chiba T; Yokosuka O; Fukai K; Kojima H; Tada M; Arai M; Imazeki F; Saisho H
Oncology; 2004; 66(6):481-91. PubMed ID: 15452378
[TBL] [Abstract][Full Text] [Related]
15. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
[TBL] [Abstract][Full Text] [Related]
16. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition?
Jung-Hynes B; Nihal M; Zhong W; Ahmad N
J Biol Chem; 2009 Feb; 284(6):3823-32. PubMed ID: 19075016
[TBL] [Abstract][Full Text] [Related]
17. Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling.
Gan L; Wang J; Xu H; Yang X
Prostate; 2011 Aug; 71(11):1158-66. PubMed ID: 21656826
[TBL] [Abstract][Full Text] [Related]
18. Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells.
Ippolito L; Marini A; Cavallini L; Morandi A; Pietrovito L; Pintus G; Giannoni E; Schrader T; Puhr M; Chiarugi P; Taddei ML
Oncotarget; 2016 Sep; 7(38):61890-61904. PubMed ID: 27542265
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
Ogura T; Tanaka Y; Tamaki H; Harada M
Int J Oncol; 2016 Jun; 48(6):2330-8. PubMed ID: 27082738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
